Product Description
Product Name: Bryxta 300 mg Injection
Active Ingredient: Bevacizumab
Strength: 300 mg
Form: Solution for Intravenous Infusion
Category: Monoclonal Antibody / Anti-Angiogenic Agent
Indication: Solid Tumors – Breast, Lung, Kidney, Cervical, Ovarian, Colorectal Cancers, and Brain Tumors
Bryxta 300 mg Injection contains Bevacizumab, a recombinant humanized monoclonal antibody that targets and inhibits vascular endothelial growth factor (VEGF). By blocking VEGF, Bryxta interferes with the tumor's ability to form new blood vessels, a process known as angiogenesis, which is essential for tumor growth and survival.
